Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and ...

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Theratechnologies (THTX) said there will be a shortage of its drug Egrifta SV on the patient level in mid-January due to a ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...

It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on ...

We don’t just sell pioneering surveillance technology, our own global exchanges use it too. Benefit from one of the most comprehensive surveillance tools on the market, used by over 170 banks ...

The Vikings added quarterback Daniel Jones to the active roster this week and questions about his role in Monday night’s game against the Rams came up during head coach Kevin O’Connell’s press ...